RxDoctor Payments Data

Stephanie Pitts

Family · Dublin, GANPI 1669937918

Payments from drug & device makers

$1,931in general payments, 2019–2025

Across 80 payments — averaging $24.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ardelyx, Inc.$322
  • QOL Medical, LLC$250
  • Johnson & Johnson$179
  • Phathom Pharmaceuticals, Inc.$166
  • Merck$132
  • AbbVie$125
  • plus $756 from 20 others

What the payments were for

  • Food & beverage$1,931100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,931 in reported general payments places this provider in the 75th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$17,821
Medicare patients
203
Services billed
306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbsrelaTenapanor Hcl25$69,692
CreonLipase/Protease/Amylase11$59,392
LinzessLinaclotide17$20,435
ClenpiqSod Picosulf/Mag Ox/Citric Ac38$6,450
Famotidine113$1,721
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates25$1,510
Pantoprazole Sodium133$1,443
Dicyclomine Hcl59$1,102
Esomeprazole Magnesium42$1,064
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine17$631
Omeprazole31$520
Lansoprazole20$456
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl25$329
Ondansetron OdtOndansetron29$285
Ondansetron Hcl18$271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$125$79,82728 claims
Ardelyx, Inc.Ibsrela$322$69,69225 claims
Ferring Pharmaceuticals Inc.Clenpiq$95$6,45038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,258 family providers in Georgia.

Other family in Dublin

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →